Nephrology and proteinuric kidney disease
Synact Pharma ApS is involved in clinical research for idiopathic membranous nephropathy with severe proteinuria, reflecting an interest in renal conditions marked by persistent loss of protein in the urine and immune-mediated kidney injury.
- Proteinuria reduction
- Idiopathic membranous nephropathy
- Renal inflammation
Its kidney-focused studies address both disease activity and urinary protein excretion as key clinical concerns in nephrology.
Rheumatology and inflammatory arthritis
The sponsor funds research in rheumatoid arthritis, with attention to early disease characterized by active inflammation and the need for effective symptom control in DMARD-naïve participants.
- Rheumatoid arthritis
- Early inflammatory arthritis
- Methotrexate combination treatment
This area places the sponsor within the therapeutic landscape of chronic autoimmune joint disease and anti-inflammatory treatment strategies.
Polymyalgia rheumatica and systemic inflammation
Synact Pharma ApS also supports studies in polymyalgia rheumatica, a condition associated with musculoskeletal pain, stiffness, and inflammatory activity in older adults.
- Polymyalgia rheumatica
- Inflammatory pain syndromes
- Musculoskeletal stiffness
Its research in this field reflects interest in disorders where controlling inflammation is central to improving daily function and disease management.
Immunology and immune-mediated disease
The sponsor’s trial portfolio spans immune-driven conditions affecting the kidneys and musculoskeletal system, indicating a focus on autoimmune disease mechanisms and inflammatory regulation.
- Autoimmune disorders
- Immune-mediated inflammation
- Chronic inflammatory disease
These studies connect immunology with therapeutic development across renal and rheumatic disease areas.
